Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

First Posted Date: 2014-04-14

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 847

Registration Number: NCT02112916

Locations: 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸
UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺
Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia

and more 209 locations

Microdose Study of Melphalan, Bortezomib and Dexamethasone

Early Phase 1

Conditions: Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-04-10

Last Posted Date: 2015-12-08

Lead Sponsor: Henrik Gregersen

Target Recruit Count: 6

Registration Number: NCT02109861

Locations: 🇩🇰
Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

Phase 2

Terminated

Conditions: Myasthenia Gravis
Systemic Lupus Erythematosus
Rheumatoid Arthritis

Interventions: Drug: Bortezomib

First Posted Date: 2014-04-03

Last Posted Date: 2019-12-03

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 11

Registration Number: NCT02102594

Locations: 🇩🇪
Charite - Universitätsmedizin Berlin, NeuroCure Clinical Research Center, Berlin, Germany
🇩🇪
Charité - Universitätsmedizin Berlin, Internal Medicine / Rheumathology, Berlin, Germany

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Plitidepsin
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-04-01

Last Posted Date: 2020-10-12

Lead Sponsor: PharmaMar

Target Recruit Count: 39

Registration Number: NCT02100657

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇪🇸
Hospital Universitario Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain

and more 4 locations

Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

Phase 2

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2014-03-13

Last Posted Date: 2017-08-29

Lead Sponsor: Yongping Zhai

Target Recruit Count: 94

Registration Number: NCT02086942

Locations: 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

Phase 2

Withdrawn

Conditions: Stage III Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Drug: bortezomib
Drug: cyclophosphamide
Drug: dexamethasone
Other: laboratory biomarker analysis
Other: quality-of-life assessment

First Posted Date: 2014-03-10

Last Posted Date: 2015-04-24

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT02082405

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Phase 2

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: linsitinib
Drug: paclitaxel
Drug: erlotinib
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-02-07

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 13

Registration Number: NCT02057380

Locations: 🇺🇸
Site US10004, La Jolla, California, United States
🇺🇸
Site US10006, Tampa, Florida, United States
🇺🇸
Site US10002, Baltimore, Maryland, United States

and more 9 locations